- April 25, 2023
- 10:00 AM - 4:00 PM ET
On April 25th, 2023, FDA hosted a virtual public meeting on Patient-Focused Drug Development for Long COVID. This meeting provided FDA the opportunity to obtain initial patient and patient representative input on the aspects of Long COVID, including how Long COVID affects their daily life, symptoms that matter most to patients, their current approaches to treating Long COVID, and what they consider when determining whether or not to participate in a clinical trial. This virtual public meeting was conducted with live translation in both English and Spanish. Closed Captioning was provided in both English and Spanish.
We encourage participants to submit written comments to the public docket by June 26, 2023: https://www.regulations.gov/document/FDA-2023-N-0363-0001 or visit www.regulations.gov and search for FDA-2023-N-0363-0001.
|Public Meeting on Patient-Focused Drug Development for Long COVID--Discussion Questions||pdf (148.84 KB)|
|Agenda - Virtual Public Meeting on Patient-Focused Drug Development for Long COVID||pdf (189.14 KB)|
|Public Meeting on Patient-Focused Drug Development for Long COVID-Slides||pdf (1.60 MB)|
|Public Meeting on Patient-Focused Drug Development for Long COVID Transcript||pdf (4.71 MB)|